Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E197 is a DOCK5 inhibitor. E197 can inhibit both mouse and human osteoclast activity. In particular, E197 prevented pathological bone loss in mice. Most interestingly, treatment with E197 did not affect osteoclast and osteoblast numbers and hence did not impair bone formation. E197 could represent a lead molecule to develop new antiosteoporotic drugs targeting the mechanism of osteoclast adhesion onto the bone.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,820.00 | |
50 mg | 8-10 weeks | $ 2,380.00 | |
100 mg | 8-10 weeks | $ 3,100.00 |
Description | E197 is a DOCK5 inhibitor. E197 can inhibit both mouse and human osteoclast activity. In particular, E197 prevented pathological bone loss in mice. Most interestingly, treatment with E197 did not affect osteoclast and osteoblast numbers and hence did not impair bone formation. E197 could represent a lead molecule to develop new antiosteoporotic drugs targeting the mechanism of osteoclast adhesion onto the bone. |
Molecular Weight | 392.9 |
Formula | C19H21ClN2O3S |
CAS No. | 2378515-04-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
E197 2378515-04-7 E 197 GS 5734-metabolite GS 441524 E-197 GS-441524 Remdesivir-metabolite, GS-5734-metabolite GS441524 GS-441524 hydrochloride GS5734-metabolite inhibitor inhibit